Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.
Biomarker
Immune response
Interferon-gamma
Mesothelioma
Outcome
Pleural effusion
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
01
07
2020
accepted:
09
05
2021
pubmed:
19
5
2021
medline:
16
10
2021
entrez:
18
5
2021
Statut:
ppublish
Résumé
Literature reports suggest that the host immune system may control Malignant Pleural Mesothelioma (MPM) growth, although its activity is limited by regulatory mechanisms. In this retrospective study, we analyzed the levels of pro-inflammatory (IL-1, IL-6, TNF), immune-regulatory (IL-10) and Th1/CTL-related cytokines (IL-12p70, IFN-γ) in the pleural exudate and their relationship with overall survival (OS) in MPM. Cytokines were quantified by multiplexed immunoassay. Concentrations were dichotomized with respect to the median value. Correlation between cytokine level and OS was assessed using univariate (Kaplan-Meier curves) and multivariate (Cox regression) analyses. Regarding outcome, tumor histology, therapies undergone and IFN-γ were independent prognostic factors of OS in a 72 MPM training cohort. Notably, high concentrations of IFN-γ halved death probability (HR of high vs low IFN-γ concentration = 0.491, 95%CI 0.3-0.8, p = 0.007). Also in patients with epithelioid histology and those receiving at least one line of therapy, high IFN-γ level was an independent factor predictive of OS (HR of high vs low IFN-γ concentration were 0.497, p = 0.007 and 0.324, p = 0.006, respectively). However, these data were not confirmed in a 77 MPM validation cohort, possibly due to the low IFN-γ levels encountered in this population, and the heterogeneous distribution of disease stages between the training and the validation cohorts. None of the other cytokines showed any effect on survival. High level of IFN-γ in pleural effusion may be associated with better survival in MPM patients and potentially serve as a prognostic biomarker. Larger prospective studies are needed to ascertain this hypothesis.
Identifiants
pubmed: 34003301
doi: 10.1007/s00262-021-02965-w
pii: 10.1007/s00262-021-02965-w
doi:
Substances chimiques
Cytokines
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3349-3355Subventions
Organisme : Italian Ministry of Health
ID : GR-2013-02356568
Organisme : Italian Ministry of Health
ID : 5x1000 Funds 2015
Organisme : Italian Ministry of Health
ID : Ricerca Corrente
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Carbone M, Adusumilli PS, Alexander HR et al (2019) Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 69:402–429. https://doi.org/10.3322/caac.21572
doi: 10.3322/caac.21572
pubmed: 31283845
pmcid: 8192079
de Gooijer CJ, Borm FJ, Scherpereel A, Baas P (2020) Immunotherapy in malignant pleural mesothelioma. Front Oncol 10:187. https://doi.org/10.3389/fonc.2020.00187
doi: 10.3389/fonc.2020.00187
pubmed: 32154179
pmcid: 7047444
Maio M, Scherpereel A, Calabrò L et al (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 18:1261–1273. https://doi.org/10.1016/S1470-2045(17)30446-1
doi: 10.1016/S1470-2045(17)30446-1
pubmed: 28729154
Scherpereel A, Mazieres J, Greillier L et al (2019) Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20:239–253. https://doi.org/10.1016/S1470-2045(18)30765-4
doi: 10.1016/S1470-2045(18)30765-4
pubmed: 30660609
Okada M, Kijima T, Aoe K et al (2019) Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese phase ii study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 25:5485–5492. https://doi.org/10.1158/1078-0432.CCR-19-0103
doi: 10.1158/1078-0432.CCR-19-0103
pubmed: 31164373
Disselhorst MJ, Quispel-Janssen J, Lalezari F et al (2019) Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 7:260–270. https://doi.org/10.1016/S2213-2600(18)30420-X
doi: 10.1016/S2213-2600(18)30420-X
pubmed: 30660511
Hegmans JP, Veltman JD, Lambers ME et al (2010) Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 181:1383–1390. https://doi.org/10.1164/rccm.200909-1465OC
doi: 10.1164/rccm.200909-1465OC
pubmed: 20167848
Aerts JGJV, de Goeje PL, Cornelissen R et al (2018) Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin Cancer Res 24:766–776. https://doi.org/10.1158/1078-0432.CCR-17-2522
doi: 10.1158/1078-0432.CCR-17-2522
pubmed: 29233904
Cornelissen R, Hegmans JPJJ, Maat APWM et al (2016) Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med 193:1023–1031. https://doi.org/10.1164/rccm.201508-1573OC
doi: 10.1164/rccm.201508-1573OC
pubmed: 26652184
Robinson BW, Robinson C, Lake RA (2001) Localised spontaneous regression in mesothelioma–possible immunological mechanism. Lung Cancer 32:197–201. https://doi.org/10.1016/s0169-5002(00)00217-8
doi: 10.1016/s0169-5002(00)00217-8
pubmed: 11325491
Yamada N, Oizumi S, Kikuchi E et al (2010) CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 59:1543–1549. https://doi.org/10.1007/s00262-010-0881-6
doi: 10.1007/s00262-010-0881-6
pubmed: 20567822
Anraku M, Cunningham KS, Yun Z et al (2008) Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 135:823–829. https://doi.org/10.1016/j.jtcvs.2007.10.026
doi: 10.1016/j.jtcvs.2007.10.026
pubmed: 18374762
Salaroglio IC, Kopecka J, Napoli F et al (2019) Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma. J Thorac Oncol 14:1458–1471. https://doi.org/10.1016/j.jtho.2019.03.029
doi: 10.1016/j.jtho.2019.03.029
pubmed: 31078776
Blum Y, Meiller C, Quetel L et al (2019) Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun 10:1333. https://doi.org/10.1038/s41467-019-09307-6
doi: 10.1038/s41467-019-09307-6
pubmed: 30902996
pmcid: 6430832
Sottile R, Tannazi M, Johansson MH et al (2019) NK- and T-cell subsets in malignant mesothelioma patients: baseline pattern and changes in the context of anti-CTLA-4 therapy. Int J Cancer 145:2238–2248. https://doi.org/10.1002/ijc.32363
doi: 10.1002/ijc.32363
pubmed: 31018250
Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958–969. https://doi.org/10.1038/nri2448
doi: 10.1038/nri2448
pubmed: 19029990
pmcid: 2724991
Chéné A-L, d’Almeida S, Blondy T et al (2016) Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages. J Thorac Oncol 11:1765–1773. https://doi.org/10.1016/j.jtho.2016.06.022
doi: 10.1016/j.jtho.2016.06.022
pubmed: 27418105
Lievense LA, Cornelissen R, Bezemer K et al (2016) Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated t cell suppression. J Thorac Oncol 11:1755–1764. https://doi.org/10.1016/j.jtho.2016.06.021
doi: 10.1016/j.jtho.2016.06.021
pubmed: 27418106
Chu GJ, van Zandwijk N, Rasko JEJ (2019) The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy. Front Oncol 9:1366. https://doi.org/10.3389/fonc.2019.01366
doi: 10.3389/fonc.2019.01366
pubmed: 31867277
pmcid: 6908501
Hmeljak J, Sanchez-Vega F, Hoadley KA et al (2018) Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 8:1548–1565. https://doi.org/10.1158/2159-8290.CD-18-0804
doi: 10.1158/2159-8290.CD-18-0804
pubmed: 30322867
pmcid: 6310008